Market Place
Sourcing Support
Huahui Health, BeOne Ink Global License for Oncology Drug HH160
30 Apr 2026 //
PR NEWSWIRE
BeOne Medicine Licenses Trispecific PD-1/CTLA-4/VEGF Antibody
28 Apr 2026 //
ENDPOINTS
China Signs Off On Amgen`s Imdelltra
10 Apr 2026 //
FIERCE PHARMA
BeOne Launches Tislelizumab For Advanced Oesophageal Cancer
10 Mar 2026 //
PHARMIWEB
BeOne Medicines Spotlights Global Oncology at 44th JPM Conference
13 Jan 2026 //
PHARMIWEB
TEVIMBRA Acquired By ZIIHERA For HER2+ Advanced GEA
06 Jan 2026 //
BUSINESSWIRE
Beone Medicines Receives FDA Fast Track For BGB-B2033
18 Dec 2025 //
PHARMIWEB
Senhwa & BeOne Medicines Ink Deal Targeting Cold Tumors
10 Dec 2025 //
PR NEWSWIRE
BRUKINSA Achieves 74% 6-Year PFS In Treatment-Naïve Cll
08 Dec 2025 //
PHARMIWEB
Sonrotoclax Shows Promise in B-Cell Malignancies at ASH 2025
07 Dec 2025 //
BUSINESSWIRE
FDA Grants Priority Review To Sonrotoclax
26 Nov 2025 //
BUSINESSWIRE
Beone Medicines Highlights B-Cell Malignancy Leadership At ASH
20 Nov 2025 //
BUSINESSWIRE
Positive Ph3 Data Support ZIIHERA as HER2 Therapy-of-Choice
17 Nov 2025 //
BUSINESSWIRE
Insysbio To Announce Its Collaboration With Beone Medicines
29 Oct 2025 //
PR NEWSWIRE
Beone Medicines Unveils TEVIMBRA Data In Lung Cancer At ESMO 2025
20 Oct 2025 //
PHARMIWEB
Beone Medicines` Sonrotoclax Receives FDA Breakthrough Therapy
13 Oct 2025 //
PHARMIWEB
BeOne Medicines Reports Sonrotoclax Success in Relapsed Lymphoma
29 Aug 2025 //
PHARMAWEB
EC Approves TEVIMBRA® as Neoadjuvant/Adjuvant NSCLC
27 Aug 2025 //
BUSINESSWIRE
BeOne Bags $885 M in Royalty Deal on Amgen`s Imdelltra
26 Aug 2025 //
FIERCE PHARMA
Europe Approves BeOne`s BRUKINSA Tablet for All Indications
21 Aug 2025 //
BUSINESSWIRE
BeOne Medicine Showcases Oncology Pipeline at R&D Day
26 Jun 2025 //
BUSINESSWIRE
BeOne Medicines gets CHMP Nod for Brukinsa tablet formulation
25 Jun 2025 //
BUSINESSWIRE
Glenmark Pharmaceuticals launches TEVIMBRA in India
25 Jun 2025 //
INDPHARMAPOST
BeOne Medicines Presents Breakthrough Data in CLL and MCL at EHA
12 Jun 2025 //
BUSINESSWIRE
BeiGene to Announce First Quarter 2025 Financial Results on May 7
17 Apr 2025 //
BUSINESSWIRE
BeiGene updates Ociperlimab (BGB-A1217) Clinical Development Program
03 Apr 2025 //
BUSINESSWIRE
BeiGene gets CHMP nod for TEVIMBRA for Lung Cancer
31 Mar 2025 //
BUSINESSWIRE
Tevimbra Wins US Approval For Advanced Esophageal Cancer
04 Mar 2025 //
BUSINESSWIRE
Tevimbra Approved In U.S. For 1L Esophageal Cancer Combo
04 Mar 2025 //
PRESS RELEASE
ImmunityBio, BeiGene Collaborate On Phase 3 Lung Cancer Trial
29 Jan 2025 //
BUSINESSWIRE
MAIA Biotech, BeiGene Partner For Phase 2 Trials In 3 Cancer Types
07 Jan 2025 //
BUSINESSWIRE
Nona Bio Update on Collaborator DualityBio`s ADC with BeiGene
03 Jan 2025 //
PR NEWSWIRE
BeiGene’s Tevimbra approved in US for first-line gastric cancer
01 Jan 2025 //
BUSINESSWIRE
Duality Biologics Achieves Milestone with BeiGene License Exercise
30 Dec 2024 //
PR NEWSWIRE
BeiGene inks $150M deal to follow cancer trail blazed by Amgen
14 Dec 2024 //
FIERCE BIOTECH
BeiGene Announces Global Licensing Agreement for MAT2A Inhibitor
12 Dec 2024 //
BUSINESSWIRE
EC Approves BeiGene’s Tevimbra for Esophageal & Gastric Cancer
27 Nov 2024 //
BUSINESSWIRE
BeiGene Proposes Name Change to BeOne Medicines for Cancer Mission
14 Nov 2024 //
BUSINESSWIRE
Indaptus Signs Clinical Supply Agreement With BeiGene
22 Oct 2024 //
GLOBENEWSWIRE
BeiGene Receives Positive CHMP Opinions For Trvimbra® Treatment
21 Oct 2024 //
BUSINESSWIRE
BeiGene Highlights Waldenström’s Macroglobulinemia At IWWM 2024
16 Oct 2024 //
BUSINESSWIRE
BeiGene launches PD-1 drug Tevimbra at 10% discount to Keytruda
04 Oct 2024 //
FIERCE PHARMA
Anbogen Inks Deal With BeiGene For Colorectal Cancer Therapy
27 Sep 2024 //
BIOSPECTRUM ASIA
BeiGene Updates On FDA Vote On PD-1 Inhibitors
26 Sep 2024 //
BUSINESSWIRE
BeiGene Receives Israeli Approval For TEVIMBRA For Oesophageal Carcinoma
17 Sep 2024 //
BUSINESSWIRE
BeiGene Announces Updates to Commercial Leadership Team
09 Sep 2024 //
BUSINESSWIRE
BeiGene Highlights TEVIMBRA Data In Lung And GI Cancers At ESMO 2024
09 Sep 2024 //
BUSINESSWIRE
BriaCell: BeiGene Supply Agreement For Bria-OTS First-In-Human Study
28 May 2024 //
GLOBENEWSWIRE
Glenmark unit ties up with BeiGene to market cancer drugs in India
21 May 2024 //
MONEYCONTROL
BeiGene`s Tislelizumab Approved in EU for Lung Cancer
23 Apr 2024 //
BUSINESSWIRE
BeiGene’s Biologics License Application for TEVIMBRA Accepted by FDA
27 Feb 2024 //
BUSINESSWIRE
BeiGene Receives Positive CHMP Opinion for Tislelizumab
26 Feb 2024 //
BUSINESSWIRE
BeiGene ends pact with Shoreline, its `entry into cell therapy`
26 Feb 2024 //
ENDPTS
BeiGene Presentations at ESMO 2023 Demonstrate Robust Clinical Strategy
16 Oct 2023 //
BUSINESSWIRE
BeiGene Announces Positive Updates After Regaining Global Rights for TEVIMBRA®
19 Sep 2023 //
PRESS RELEASE
BeiGene Announces Positive CHMP Opinion for Tislelizumab as a Treatment for Advanced or Metastatic ESCC
21 Jul 2023 //
BUSINESSWIRE
FDA completes inspection for Novartis, BeiGene`s anti-PD-1 drug from China
18 Jul 2023 //
ENDPTS
BeiGene Announces FDA Acceptance of sNDA for Fifth BRUKINSA® Indication
12 Jul 2023 //
BUSINESSWIRE
